1. Introduction {#sec1-metabolites-09-00014}
===============

The global prevalence of diabetes among adults is soaring, rising from 4.7% in 1980 to 8.5% in 2014 \[[@B1-metabolites-09-00014]\]. Type 2 diabetes comprises 90--95% of diabetes, and is characterized by high blood glucose, insulin resistance, and relative insulin deficiency \[[@B2-metabolites-09-00014]\]. The pathogenesis of type 2 diabetes is complex and involves interaction of genetic and environmental influences. Several epidemiologic studies using metabolomics strategies have reported that the increase of certain essential amino acids such as branched-chain amino acids (BCAAs) and aromatic amino acids (AAAs) was associated with a high risk of type 2 diabetes in Western and Asian populations \[[@B3-metabolites-09-00014],[@B4-metabolites-09-00014],[@B5-metabolites-09-00014],[@B6-metabolites-09-00014],[@B7-metabolites-09-00014],[@B8-metabolites-09-00014]\]. Further, Tilin et al. \[[@B9-metabolites-09-00014]\] and Lee et al. \[[@B10-metabolites-09-00014]\] reported ethnical differences in blood levels of BCAAs and AAAs and suggested that these differences may add explanatory insights into the increased risk of diabetes in multiethnic cohorts. These observations provide a new angle on the pathogenesis of type 2 diabetes, thus attracting worldwide attention. However, recent studies have shown conflicting data on the effects of BCAAs on glucose metabolism and insulin resistance \[[@B11-metabolites-09-00014],[@B12-metabolites-09-00014],[@B13-metabolites-09-00014]\]. In a recent prospective study, Zheng et al. reported that high intake of BCAAs is associated with an increased risk of type 2 diabetes in three large cohorts of US women and men \[[@B11-metabolites-09-00014]\], while one study conducted in a Japanese population found that a high intake of BCAAs is associated with a low risk of type 2 diabetes \[[@B13-metabolites-09-00014]\]. Compared to the essential amino acids, non-essential amino acids can be produced in the body and are less influenced by the dietary factors, and their concentrations may be more related to the metabolic disorders in type 2 diabetes. In this study, we thus aimed to simultaneously examine and verify the relation of both essential and non-essential amino acids with both prevalent and incident type 2 diabetes in a population-based cohort study, the Singapore Chinese Health Study (SCHS).

2. Results {#sec2-metabolites-09-00014}
==========

2.1. Method Validation {#sec2dot1-metabolites-09-00014}
----------------------

A total of 19 amino acids, including 9 essential (histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, and valine) and 10 non-essential amino acids (alanine, arginine, asparagine, aspartic acid, glutamic acid, glutamine, glycine, proline, serine, and tyrosine), were quantified in this study ([Supplementary Table S1](#app1-metabolites-09-00014){ref-type="app"}). The proposed analytical method was validated for limit of detection (LOD), linearity, recovery, accuracy, and precision ([Supplementary Table S2](#app1-metabolites-09-00014){ref-type="app"}).

2.2. Participant Characteristics {#sec2dot2-metabolites-09-00014}
--------------------------------

[Table 1](#metabolites-09-00014-t001){ref-type="table"} shows baseline characteristics of the participants, in which prevalent and incident type 2 diabetes were presented separately. In this study, we divided the cases into prevalent and incident type 2 diabetes cases according to their baseline HbA1c levels: prevalent cases with HbA1c ≥ 6.5% (47.5 mmol/mol) and incident cases with HbA1c \< 6.5% (47.5 mmol/mol). Cases with prevalent and incident type 2 diabetes had higher levels of random glucose, BMI, triglycerides and lower levels of high-density lipoprotein (HDL)-cholesterol than controls at baseline (*p* ≤ 0.001), and they were also more likely to report a history of hypertension. As noted, 27.3% participants (166 out of 608) were fasted before blood collection.

2.3. Associations Between Amino Acids and Type 2 Diabetes {#sec2dot3-metabolites-09-00014}
---------------------------------------------------------

Associations between amino acids and the risk for prevalent type 2 diabetes are shown in [Table 2](#metabolites-09-00014-t002){ref-type="table"}. After adjustment for confounders, including BMI, history of hypertension, smoking status, HDL-cholesterol, and triglycerides, 10 amino acids were associated with prevalent type 2 diabetes at *p* \< 0.05, including 5 essential (isoleucine, leucine, lysine, phenylalanine, and valine) and 5 non-essential (alanine, glutamic acid, glutamine, glycine, and tyrosine) amino acids. All the 10 amino acids were significant with an FDR cut-off of 0.1. Although 0.05 is commonly used as a cutoff limit for FDR in the discovery of metabolic signatures, the metabolites with FDR between 0.05 and 0.1 are still considered marginally significant. To avoid missing potential biomarker candidates associated with risk for type 2 diabetes, we applied 0.1 as the cutoff value for FDR. The associations between amino acids and the risk for incident type 2 diabetes were shown in [Supplementary Table S3](#app1-metabolites-09-00014){ref-type="app"}. After adjustment for BMI, history of hypertension, smoking status, HDL-cholesterol, and triglycerides, 6 amino acids were associated with incident type 2 diabetes at *p* \< 0.05, including 4 essential (isoleucine, leucine, tryptophan, and valine) and 2 non-essential (glutamine and tyrosine) amino acids. However, none of the 6 amino acids were significant at FDR \< 0.1. Of these, five differential amino acids were common to prevalent and incident type 2 diabetes, including glutamic acid, tyrosine, and three BCAAs (leucine, isoleucine, and valine). The associations of 5 common amino acids with prevalent type 2 diabetes were stronger than those with incident type 2 diabetes, except tyrosine, for which the association with incident type 2 diabetes was more evident.

In our study, certain amino acid changes due to fasting status were observed ([Supplementary Table S4](#app1-metabolites-09-00014){ref-type="app"}). However, stratification by fasting status showed that fasting had no effect on the associations between amino acids with prevalent and incident type 2 diabetes (*p* for interaction \> 0.5) ([Supplementary Tables S5 and S6](#app1-metabolites-09-00014){ref-type="app"}). This is possibly because the proportion of type 2 diabetes cases was equally distributed among fasting and non-fasting participants (*p* \> 0.05) ([Table 1](#metabolites-09-00014-t001){ref-type="table"}). They are the reasons why we did not include fasting status in the models. In contrast, we reasoned that smoking is an important risk factor for type 2 diabetes and thus included it in the models.

2.4. Predictive Value of Amino Acids for Incident Type 2 Diabetes {#sec2dot4-metabolites-09-00014}
-----------------------------------------------------------------

We evaluated the predictive performance of amino acids for the risk of incident type 2 diabetes using c- statistics, and IDI and NRI indexes ([Table 3](#metabolites-09-00014-t003){ref-type="table"}). Adding the 19 amino acids individually did not significantly improve AUCROC values compared to base model of BMI, history of hypertension, smoking status, HDL-cholesterol, and triglycerides, whereas IDI and NRI statistics showed that valine and tyrosine could improve risk reclassification of incident type 2 diabetes at *p* \< 0.05. In addition to individual amino acid, we explored the predictive performance of certain amino acid combinations through binary logistic regression, including combinations of 6 amino acids associated with incident type 2 diabetes (combination 1), 9 essential amino acids (combination 2), 10 non-essential amino acids (combination 3), and all the 19 amino acids (combination 4). We found that all the 4 combinations could significantly improve risk reclassification of incident type 2 diabetes with a *p* \< 0.01 in IDI and NRI statistics, yet only the combination 4 led to a significant increase in area under the receiver operating characteristic curve (AUCROC) value (*p* = 0.04).

3. Discussion {#sec3-metabolites-09-00014}
=============

In this case-control study, we simultaneously quantified 9 essential and 10 non-essential amino acids using LC-MS/MS. The increase of 6 essential (isoleucine, leucine, lysine, phenylalanine, tryptophan, and valine) and 3 non-essential (alanine, glutamic acid, and tyrosine) amino acids was associated with a higher risk for prevalent and/or incident type 2 diabetes. On the other hand, accumulation of glutamine and glycine was associated with a lower risk of type 2 diabetes. Notably, we found that these associations were influenced by random glucose levels. With further adjustment for random glucose, none of these amino acids remained significant associations with type 2 diabetes. Moreover, we examined the predictive performance of amino acids for type 2 diabetes and found that valine and tyrosine showed positive predictive value for diabetes risk in this Chinese population.

Essential amino acids such as BCAAs are mainly derived from dietary intake and are metabolized in skeletal muscle and adipose tissue \[[@B14-metabolites-09-00014]\]. Numerous epidemiologic studies have identified blood BCAAs as among the most consistent and important metabolites associated with insulin resistance \[[@B3-metabolites-09-00014],[@B15-metabolites-09-00014],[@B16-metabolites-09-00014],[@B17-metabolites-09-00014]\]. In consistent with these studies, we found that BACCs (isoleucine, leucine, and valine) were significantly increased in prevalent and incident type 2 diabetes cases compared to controls. Although not completely understood, there exists several possible mechanisms underlying the association between BCAAs and the risk of type 2 diabetes. First, a recent study by Pedersen et al. shown that altered intestinal microbiota impacted BCAA levels and may contribute to insulin resistance \[[@B18-metabolites-09-00014]\]. Further, BCAAs can increase skeletal muscle glucose uptake and stimulate glycogen synthesis in an insulin-independent manner through phosphatidylinositol 3-kinase or protein kinase C \[[@B19-metabolites-09-00014]\]. In addition, the interplay of adipose tissue, BCAA metabolism, and glucose homeostasis was reported recently \[[@B20-metabolites-09-00014]\]. BCAAs may produce more catabolic intermediates such as propionyl CoA and succinyl CoA, leading to accumulation of incompletely oxidized fatty acids and glucose.

AAAs, particularly phenylalanine and tyrosine, have been reported to be elevated together with BCAAs in obesity-related insulin resistance \[[@B3-metabolites-09-00014],[@B15-metabolites-09-00014],[@B21-metabolites-09-00014],[@B22-metabolites-09-00014]\]. In line with these studies, we found that phenylalanine and tyrosine were significantly increased in prevalent and/or incident type 2 diabetes cases compared to controls. In addition, tryptophan was found to be significantly increased in incident type 2 diabetes cases compared to controls in our study. Tryptophan can be metabolized to several kinds of physiologically active metabolites such as kynurenine, kynurenic acid, and serotonin via two metabolic pathways: tryptophan--kynurenine and tryptophan--methoxyindole. The changes in the two pathways have been related to several pathophysiological mechanisms of type 2 diabetes \[[@B23-metabolites-09-00014]\].

Besides well-recognized BCAAs and AAAs, we identified four non-essential amino acids (alanine, glutamic acid, glutamine, and glycine) associated with prevalent and/or incident type 2 diabetes. Among these four amino acids, alanine and glutamic acid were positively associated with risk of type 2 diabetes; glutamine and glycine were negatively associated. The finding of inverse associations between glutamine and glycine and the risk for type 2 diabetes is in line with a recent meta-analysis \[[@B16-metabolites-09-00014]\]. Alanine has recently been associated with future hyperglycemia and the risk for diabetes \[[@B24-metabolites-09-00014],[@B25-metabolites-09-00014],[@B26-metabolites-09-00014]\]. Glutamic acid is derived from BCAAs, catalyzed by branched-chain aminotransferase. A report from the Framingham offspring study showed that glutamic acid was positively associated with insulin resistance \[[@B27-metabolites-09-00014]\]. In this study, the increase of glutamic acid was strongly associated with the risk for prevalent and incident type 2 diabetes.

The strength of this study is its prospective design and hence the presumed lack of recall bias in exposure data prior to type 2 diabetes diagnosis. Furthermore, the roles of essential and non-essential amino acids were estimated in parallel in this study. However, several limitations in our study exist. First, more than 70% of serum samples were non-fasting, and may thus affect the metabolite levels. To address this limitation, we conducted a stratified analysis by fasting status and no significant differences were observed between fasting and non-fasting samples. Second, the levels of essential amino acids are partly influenced by the dietary habits, yet the information regarding the diet was not available for further investigation. Third, the samples size is relatively small, and the potential of amino acids for risk prediction of type 2 diabetes in Chinese need to be validated externally in a large population.

4. Materials and Methods {#sec4-metabolites-09-00014}
========================

4.1. Chemicals and Reagents {#sec4dot1-metabolites-09-00014}
---------------------------

LC-MS grade methanol, acetonitrile, formic acid, ammonium formate, and standards including amino acid standard mixture (AAS18), tryptophan, glutamine, and asparagine were purchased from Sigma-Aldrich (St. Louis, MO, USA). Isotopically labeled amino acid mix standard (MSK-A2-1.2) was purchased from Cambridge Isotope Laboratories (Tewksbury, MA, USA). Distilled water was purified "in-house" using a Milli-Q purification system (Bedford, MA, USA).

4.2. Study Population {#sec4dot2-metabolites-09-00014}
---------------------

The participants were from the SCHS. Detailed information of recruitment and follow-up visits for SCHS has been published previously \[[@B8-metabolites-09-00014],[@B28-metabolites-09-00014]\]. Briefly, 63,257 Chinese aged 45--74 years were recruited in 1993-1998. The first follow-up visit was conducted in 1999--2004, and 32,575 participants donated the morning blood samples, in which fasting was not required. The second follow-up visit was conducted in 2006--2010. Because of the logistical and funding constraints of this study, we randomly selected 608 participants for this study, including 304 cases and 304 controls. The cases were free of diagnosed diabetes, cardiovascular disease, and cancer during the first visit when blood was collected (baseline), while reported to have type 2 diabetes during the second visit. The controls were free of aforementioned diseases both at first and second visits. The age (±3 years), sex, and date of blood collection (±6 months) of cases and controls were individually matched. The baseline serum samples were used in this study. All participants voluntarily joined this study, gave informed consents, and completed questionnaires that provided information including age, sex, demographical factors, lifestyle habits, and medical history. This study was approved by the Institutional Ethics Review Board at the National University of Singapore (ethic code: NUS-IRB code 06-027).

4.3. Prevalent and Incident Type 2 Diabetes: Patient Regrouping {#sec4dot3-metabolites-09-00014}
---------------------------------------------------------------

In Singapore, diagnostic tests of diabetes at the time of two visits (1999--2004 and 2006--2010) were made according to the 1997 American Diabetes Association (ADA) criteria \[[@B29-metabolites-09-00014]\], which were based on symptoms plus random glucose concentrations, fasting glucose concentrations or 2-h glucose tolerance tests. Here, random glucose concentration presents a blood glucose measurement that was carried out either with blood taken from a fasting status, or a non-fasting status during the study visit. In 2010, HbA1c ≥ 6.5% (47.5 mmol/mol) was proposed by ADA as an additional diagnostic criterion \[[@B30-metabolites-09-00014]\]. In line with the update of diagnostic criteria, we divided the 304 cases into prevalent and incident type 2 diabetes cases according to their baseline HbA1c levels: cases with HbA1c ≥ 6.5% (47.5 mmol/mol) at baseline were defined as prevalent cases (*n* = 144); cases with HbA1c \< 6.5% (47.5 mmol/mol) at baseline were classified as incident cases (*n* = 160). HbA1c values in the controls were all \< 6.0% (42.1 mmol/mol).

4.4. Lipid Assays {#sec4dot4-metabolites-09-00014}
-----------------

Blood concentrations of-cholesterol and triglycerides were measured using colorimetric method on a chemistry analyzer (AU5800; Beckman Coulter, Brea, CA, USA).

4.5. Amino Acid Quantification {#sec4dot5-metabolites-09-00014}
------------------------------

Serum samples (50 μL) were diluted with 50μl of distilled water containing isotope labeled amino acid mix standard (75 μM) as internal standards. The mixture was treated by 500 μL of ice-cold methanol for protein precipitation. After centrifugation at 20,817 g for 15 min at 4°C, the supernatant fraction was filtered by Thermo Scientific™ national 750µL micro-centrifugal filters (PTFE membrane, 0.2 µm pore size, non-sterile). The filtrate was dried by 99.9% purity of nitrogen (N2) and reconstituted in 200 μL of acetonitrile/water (90:10, v/v) before analysis.

Quantitative analysis of amino acids was performed on an Agilent 1200 HPLC system (Waldbronn, Germany) coupled to a 6410 Triple Quadrupole mass spectrometer (Waldbronn, Germany) equipped with an electrospray ionization source in positive ion mode. Amino acids were separated by using an Acquity UPLC BEH Amide column (2.1 mm × 100 mm, 1.7 µm, Waters). The mobile phases A (30% acetonitrile with 0.1% formic acid and 10 mmol/L ammonium formate) and B (95% acetonitrile with 0.1% formic acid and 10 mmol/L ammonium formate) were employed. The gradient program was: 0--1 min, 100% B; 1--2 min, 100--92% B; 2--10 min, 92--85% B; 10--12 min, 85--60% B; 12--14 min, 60--40% B; 14--15 min, 40--15% B; 15--19 min, 15%B; 19--19.5 min, 15--100% B. The flow rate was set at 0.5 mL/min. The column temperature and injection volume were set at 40°C and 5 μL, respectively. The mass spectrum was acquired in the multiple reaction monitoring (MRM) mode with a capillary voltage of 3500 V, gas temperature of 350°C, gas flow of 12 L/min and nebulizer nitrogen gas flow rate of 30 psi. The retention time, MRM transition, fragmentor voltage, and collision energy (CE) are shown in [Supplementary Table S1](#app1-metabolites-09-00014){ref-type="app"}.

All the 304 paired samples were analyzed blindly in 8 completely independent batches, i.e., 38 paired samples in each batch. The stable isotope labeled internal standards were used in all the sample extractions and for calibration. The quality control (QC) samples were prepared by spiking certain amount native and labeled standards into a pooled plasma from all participants, and six QCs were analyzed along with the samples in each batch to ensure the reliability of the method and the instrument stability.

4.6. Statistical Analysis {#sec4dot6-metabolites-09-00014}
-------------------------

Demographic and clinical variables of participants were presented as mean ± standard deviation (SD) for continuous data, and proportions for categorical data. Their differences between cases and controls were tested using paired t-test for continuous variables and chi-square test for categorical variables. All the amino acids measured were detected in all of the 608 serum samples, i.e., there was no missing value. Odds ratio (OR) with 95% confidence interval (CI) and *p* value for the associations between amino acids and type 2 diabetes were calculated by conditional logistic regression models, with adjustment for confounding factors, including BMI, history of hypertension, smoking status, HDL-cholesterol, and triglycerides. The OR was represented both as tertiles and per SD increment for each amino acid, and *p* value was corrected for multiple testing via false discovery rate (FDR) using the Benjamini-Hochberg method. The correlations of amino acids with random glucose and HbA1c levels were examined in controls using Pearson partial correlation analysis, adjusting for age, sex, and BMI. The c-statistic (i.e., the area under the receiver operating characteristic curve (AUCROC)) was calculated to assess the predictive utility of each metabolite by examining the improvement in discrimination. Because of the limitation of AUCROC: it is insensitive to detect clinically important risk differences \[[@B31-metabolites-09-00014]\], we evaluated the integrated discrimination improvement (IDI) and category-free net reclassification improvement (NRI) indexes as well. Statistical analyses were performed using IBM SPSS Statistics 24 and Stata version 14.0. A two-sided *p* \<0.05 or FDR \<0.1 was considered as statistically significant.

5. Conclusions {#sec5-metabolites-09-00014}
==============

In conclusion, this study demonstrates the previous reports of strong associations between essential amino acids, particularly BCAAs and AAAs, and the risk for prevalent and incident type 2 diabetes. Further, the associations of non-essential amino acids and the risk for prevalent and incident type 2.
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metabolites-09-00014-t001_Table 1

###### 

Baseline characteristics of the participants.

  Baseline Characteristics         Prevalent Type 2 Diabetes   Incident Type 2 Diabetes                                       
  -------------------------------- --------------------------- -------------------------- --------- ------------ ------------ ---------
  HbA1c                                                                                                                       
   %                               7.7 ± 1.6                   5.6 ± 0.3                            5.9 ± 0.4    5.5 ± 0.2    
   mmol/mol                        60.7 ± 12.6                 37.7 ± 2.0                           41.0 ± 2.8   36.6 ± 1.3   
  Random glucose (mmol/L)          8.8 ± 4.2                   4.9 ± 1.3                  \<0.001   5.8 ± 2.0    4.9 ± 1.2    \<0.001
  Age (years)                      62.7 ± 6.1                  62.7 ± 5.9                 0.834     61.6 ± 5.6   61.9 ± 6.0   0.163
  Sex, n (%)                                                                              1.000                               1.000
   Male                            62 (43.1)                   62 (43.1)                            79 (49.4)    79 (49.4)    
   Female                          82 (56.9)                   82 (56.9)                            81 (50.6)    81 (50.6)    
  BMI (kg/m^2^)                    24.6 ± 3.6                  23.1 ± 3.3                 \<0.001   24.6 ± 3.4   22.6 ± 3.5   \<0.001
  History of hypertension, n (%)                                                          0.066                               \<0.001
   No                              84 (58.3)                   99 (68.7)                            75 (46.9)    118 (73.8)   
   Yes                             60 (41.7)                   45 (31.3)                            85 (53.1)    42 (26.3)    
  Smoking status, n (%)                                                                   0.700                               0.721
   Non-smoker                      99 (68.8)                   102 (70.8)                           106 (66.3)   109 (68.1)   
   Smoker                          45 (31.2)                   42 (29.2)                            54 (33.7)    51 (31.9)    
  Alcohol consumption, n (%)                                                              0.733                               0.867
   \< 1 drink/week                 125 (86.8)                  123 (85.4)                           139 (86.9)   140 (87.5)   
   ≥1 drink/week                   19 (13.2)                   21 (14.6)                            21 (13.1)    20 (12.5)    
  Physical activity, n (%)                                                                0.879                               0.689
   \<0.5 hours/week                118 (81.9)                  117 (81.3)                           125 (78.1)   122 (76.3)   
   ≥0.5 hours/week                 26 (18.1)                   27 (18.7)                            35 (21.9)    38 (23.7)    
  Education, n (%)                                                                        0.405                               0.657
   None                            37 (25.7)                   31 (21.5)                            29 (18.1)    26 (16.3)    
   Primary and above               107 (74.3)                  113 (78.5)                           131 (81.9)   134 (83.7)   
  Fasting status, n (%)                                                                   0.372                               0.360
   Non-fasting                     96 (66.7)                   103 (71.5)                           118 (73.8)   125 (78.1)   
   Fasting                         48 (33.3)                   41 (28.5)                            42 (26.3)    35 (21.9)    
  HDL-cholesterol (mmol/L)         1.1 ± 0.2                   1.2 ± 0.3                  \<0.001   1.1 ± 0.3    1.2 ± 0.3    \<0.001
  Triglycerides (mmol/L)           2.6 ± 1.9                   2.0 ± 1.3                  0.001     2.4 ± 1.3    1.7 ± 0.9    \<0.001

Data are presented as mean ± standard deviation for continuous variables, and n (%) for categorical variables. The *p* values were calculated by paired t-test for continuous variables and Chi-square test for categorical variables.

metabolites-09-00014-t002_Table 2

###### 

The associations between amino acids and prevalent type 2 diabetes (*n* = 144).

  Amino Acids                 OR Across Tertiles (T) ^a^   OR Per SD Increment ^a^                                                                      
  --------------------------- ---------------------------- ------------------------- -------------------- ------- ------- ------------------- --------- -------
  Essential amino acids                                                                                                                                 
  Valine                      1.00                         5.00 (2.05, 12.18)        5.13 (2.05, 12.86)   0.001   0.006   1.85 (1.30, 2.64)   0.001     0.006
  Leucine                     1.00                         2.43 (1.24, 4.73)         2.63 (1.27, 5.48)    0.007   0.033   1.55 (1.12, 2.13)   0.008     0.038
  Isoleucine                  1.00                         2.79 (1.39, 5.62)         2.22 (1.08, 4.57)    0.026   0.068   1.34 (0.98, 1.85)   0.069     0.133
  Phenylalanine               1.00                         1.99 (1.03, 3.84)         2.12 (1.05, 4.26)    0.030   0.068   1.44 (1.05, 1.96)   0.022     0.073
  Lysine                      1.00                         0.88 (0.45, 1.74)         2.28 (1.11, 4.68)    0.032   0.068   1.42 (1.04, 1.94)   0.027     0.073
  Methionine                  1.00                         2.75 (1.39, 5.46)         1.86 (0.92, 3.80)    0.077   0.124   1.21 (0.90, 1.65)   0.209     0.265
  Threonine                   1.00                         0.83 (0.42, 1.63)         0.54 (0.27, 1.08)    0.085   0.124   0.81 (0.62, 1.07)   0.134     0.219
  Tryptophan                  1.00                         0.62 (0.31, 1.25)         1.79 (0.78, 4.14)    0.222   0.301   1.43 (0.97, 2.11)   0.070     0.133
  Histidine                   1.00                         1.49 (0.75, 2.93)         0.85 (0.44, 1.65)    0.644   0.723   0.81 (0.62, 1.07)   0.138     0.219
  Non-essential amino acids                                                                                                                             
  Glutamic acid               1.00                         2.96 (1.37, 6.39)         4.04 (1.79, 9.12)    0.001   0.006   1.89 (1.34, 2.67)   \<0.001   0.006
  Alanine                     1.00                         1.73 (0.82, 3.65)         3.41 (1.63, 7.14)    0.001   0.006   1.73 (1.23, 2.42)   0.001     0.006
  Glutamine                   1.00                         0.66 (0.27, 1.62)         0.32 (0.12, 0.87)    0.017   0.057   0.65 (0.44, 0.97)   0.035     0.083
  Glycine                     1.00                         0.51 (0.26, 1.00)         0.47 (0.26, 0.87)    0.018   0.057   0.73 (0.55, 0.96)   0.024     0.073
  Tyrosine                    1.00                         1.82 (0.90, 3.66)         2.12 (1.03, 4.37)    0.044   0.084   1.23 (0.90, 1.68)   0.186     0.252
  Serine                      1.00                         1.27 (0.70, 2.32)         1.81 (0.93, 3.52)    0.083   0.124   1.21 (0.91, 1.60)   0.186     0.252
  Asparagine                  1.00                         1.20 (0.63, 2.29)         0.66 (0.32, 1.36)    0.299   0.379   0.86 (0.63, 1.18)   0.362     0.430
  Arginine                    1.00                         0.95 (0.47, 1.90)         0.86 (0.46, 1.62)    0.647   0.723   0.92 (0.71, 1.20)   0.541     0.605
  Proline                     1.00                         1.70 (0.83, 3.47)         1.00 (0.49, 2.07)    0.935   0.970   1.00 (0.76, 1.32)   0.997     0.997
  Aspartic acid               1.00                         0.67 (0.33, 1.38)         1.04 (0.43, 2.50)    0.970   0.970   1.05 (0.78, 1.41)   0.767     0.810

Prevalent cases were defined as those had HbA1c ≥ 6.5% (47.5 mmol/mol) but did not report to have diagnosed diabetes at baseline when blood samples were collected (1999--2004), while reported to have diagnosed diabetes during the follow-up (2006--2010). ^a^ Odds ratio (OR) with 95% confidence interval (CI) and *p* values were calculated by conditional logistic regression after adjustment for BMI, history of hypertension, smoking status, HDL-cholesterol, and triglycerides.

metabolites-09-00014-t003_Table 3

###### 

Potential of amino acids for risk prediction of incident type 2 diabetes (*n* = 160).

  Amino acids       C-Statistics ^a^    IDI    NRI      
  ----------------- ------------------- ------ -------- --------
   Essential                                            
    Valine          0.76 (0.70, 0.81)   0.34   0.03     0.01
    Tryptophan      0.75 (0.70, 0.81)   0.51   0.05     0.09
    Phenylalanine   0.76 (0.70, 0.81)   0.33   0.07     0.06
    Leucine         0.75 (0.70, 0.80)   0.46   0.08     0.03
    Isoleucine      0.75 (0.70, 0.80)   0.82   0.20     0.91
    Histidine       0.75 (0.70, 0.80)   0.60   0.31     0.02
    Methionine      0.75 (0.70, 0.80)   0.88   0.44     0.99
    Lysine          0.75 (0.70, 0.80)   0.94   0.59     0.15
    Threonine       0.75 (0.69, 0.80)   0.61   0.91     0.99
   Non-essential                                        
    Tyrosine        0.76 (0.71, 0.81)   0.21   0.02     0.01
    Aspartic acid   0.75 (0.70, 0.81)   0.36   0.10     0.50
    Glycine         0.75 (0.70, 0.81)   0.38   0.14     0.99
    Alanine         0.75 (0.70, 0.80)   0.62   0.31     0.31
    Glutamic acid   0.75 (0.70, 0.80)   0.76   0.38     0.37
    Arginine        0.75 (0.69, 0.80)   0.92   0.69     0.50
    Proline         0.75 (0.70, 0.80)   0.56   0.77     0.37
    Serine          0.75 (0.69, 0.80)   0.87   0.80     0.58
    Glutamine       0.75 (0.70, 0.80)   0.89   0.83     0.65
    Asparagine      0.75 (0.69, 0.80)   0.08   0.99     0.65
   Combinations                                         
    Combination 1   0.76 (0.71, 0.82)   0.15   \<0.01   \<0.01
    Combination 2   0.77 (0.72, 0.82)   0.12   \<0.01   \<0.01
    Combination 3   0.77 (0.72, 0.82)   0.07   \<0.01   \<0.01
    Combination 4   0.78 (0.73, 0.83)   0.04   \<0.01   \<0.01

IDI, integrated discrimination improvement; NRI, category-free net reclassification improvement. Combination 1: 6 amino acids associated with incident type 2 diabetes, including isoleucine, leucine, tryptophan, valine, glutamine, and tyrosine. Combination 2: 9 essential amino acids, including histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, and valine. Combination 3: 10 non-essential amino acids, including alanine, arginine, asparagine, aspartic acid, glutamic acid, glutamine, glycine, proline, serine, and tyrosine. Combination 4: all the 19 measure amino acids. ^a^ AUC increment of amino acids after adding in the basic model (AUC = 0.75, 95% CI \[0.69, 0.80\]) of BMI, history of hypertension, smoking, HDL-cholesterol, and triglycerides.
